Mark M. A. Mintun

Mark M. A. Mintun's AcademicInfluence.com Rankings

Mark M. A. Mintun

Engineering

#2574

World Rank

#3521

Historical Rank

Biomedical Engineering

#73

World Rank

#74

Historical Rank

Electrical Engineering

#480

World Rank

#534

Historical Rank

engineering Degrees

Mark M. A. Mintun

Philosophy

#3865

World Rank

#6171

Historical Rank

Logic

#1467

World Rank

#2226

Historical Rank

philosophy Degrees

Download Badge

Engineering
Philosophy

Why Is Mark M. A. Mintun Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Mark M. A. Mintun's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Improved Assessment of Significant Activation in Functional Magnetic Resonance Imaging (fMRI): Use of a Cluster‐Size Threshold (1995) (3293)
Positron emission tomographic studies of the cortical anatomy of single-word processing (1988) (2517)
Molecular, Structural, and Functional Characterization of Alzheimer's Disease: Evidence for a Relationship between Default Activity, Amyloid, and Memory (2005) (1905)
Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands (2007) (1854)
Nonoxidative glucose consumption during focal physiologic neural activity. (1988) (1717)
Brain work and brain imaging. (2006) (1487)
Depression Duration But Not Age Predicts Hippocampal Volume Loss in Medically Healthy Women with Recurrent Major Depression (1999) (1357)
The default mode network and self-referential processes in depression (2009) (1202)
Spatial working memory in humans as revealed by PET (1993) (1189)
Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: an fMRI study (2001) (1181)
Positron Emission Tomographic Studies of the Processing of Singe Words (1989) (1169)
Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. (2015) (1112)
Brain blood flow measured with intravenous H2(15)O. II. Implementation and validation. (1983) (1060)
Resting-state functional MRI in depression unmasks increased connectivity between networks via the dorsal nexus (2010) (1025)
A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography (1984) (982)
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans (2006) (968)
Use of florbetapir-PET for imaging beta-amyloid pathology. (2011) (938)
Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. (2007) (881)
APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging (2010) (777)
[11C]PIB in a nondemented population (2006) (767)
Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis (2016) (716)
Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study (2012) (652)
Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease (2018) (628)
Positron emission tomography study of voluntary saccadic eye movements and spatial working memory. (1996) (596)
Brain oxygen utilization measured with O-15 radiotracers and positron emission tomography. (1984) (591)
The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET (2015) (536)
Amyloid Plaques Disrupt Resting State Default Mode Network Connectivity in Cognitively Normal Elderly (2010) (534)
Amyloid deposition, hypometabolism, and longitudinal cognitive decline (2012) (534)
Regional aerobic glycolysis in the human brain (2010) (532)
Enhanced Detection of Focal Brain Responses Using Intersubject Averaging and Change-Distribution Analysis of Subtracted PET Images (1988) (520)
Interference and Facilitation Effects during Selective Attention: An H2 15O PET Study of Stroop Task Performance (1995) (480)
Forebrain activation in REM sleep: an FDG PET study 1 Presented in abstract form at the Society for Neuroscience Meeting, 1996. 1 (1997) (478)
Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. (2015) (476)
Potential antecedent marker of Alzheimer disease (2006) (474)
Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. (2009) (470)
Altered Emotional Interference Processing in Affective and Cognitive-Control Brain Circuitry in Major Depression (2008) (451)
A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. (2001) (450)
Functional hypofrontality and working memory dysfunction in schizophrenia. (1998) (410)
Anterior cingulate gyrus dysfunction and selective attention deficits in schizophrenia: [15O]H2O PET study during single-trial Stroop task performance. (1997) (404)
APOE4 Allele Disrupts Resting State fMRI Connectivity in the Absence of Amyloid Plaques or Decreased CSF Aβ42 (2010) (404)
Breast cancer: PET imaging of estrogen receptors. (1988) (401)
Mapping human visual cortex with positron emission tomography (1986) (397)
YKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer's Disease (2010) (393)
In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM (2003) (359)
Brain regions responsive to novelty in the absence of awareness. (1997) (351)
Amyloid-β Imaging with Pittsburgh Compound B and Florbetapir: Comparing Radiotracers and Quantification Methods (2013) (349)
Spatial correlation between brain aerobic glycolysis and amyloid-β (Aβ) deposition (2010) (346)
Noninvasive functional brain mapping by change-distribution analysis of averaged PET images of H215O tissue activity. (1989) (344)
Blood flow and oxygen delivery to human brain during functional activity: Theoretical modeling and experimental data (2001) (332)
Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report. (2003) (331)
Donanemab in Early Alzheimer's Disease. (2021) (328)
Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease (2009) (323)
Performance Characteristics of Amyloid PET with Florbetapir F 18 in Patients with Alzheimer's Disease and Cognitively Normal Subjects (2012) (323)
Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. (2011) (322)
Neuroanatomical correlates of a lactate-induced anxiety attack. (1989) (315)
Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β‐amyloid (2013) (300)
Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. (2009) (300)
An automated method for rotational correction and centering of three-dimensional functional brain images. (1992) (290)
Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans (2011) (288)
Decreased cerebrospinal fluid Aβ42 correlates with brain atrophy in cognitively normal elderly (2009) (286)
Regional cerebral blood flow during word and nonword reading (1997) (279)
Automated detection of the intercommissural line for stereotactic localization of functional brain images. (1993) (271)
Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition (2017) (269)
Exercise and Alzheimer's disease biomarkers in cognitively normal older adults (2010) (263)
Exercise Engagement as a Moderator of the Effects of APOE Genotype on Amyloid Deposition. (2012) (248)
Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. (2004) (243)
A Noninvasive Approach to Quantitative Functional Brain Mapping with H215O and Positron Emission Tomography (1984) (242)
Measurement of Longitudinal β-Amyloid Change with 18F-Florbetapir PET and Standardized Uptake Value Ratios (2015) (240)
A Highly Accurate Method of Localizing Regions of Neuronal Activation in the Human Brain with Positron Emission Tomography (1989) (237)
Positron Tomographic Assessment of 16α-[18F] Fluoro-17β-Estradiol Uptake in Metastatic Breast Carcinoma (1991) (233)
The effect of non-insulin-dependent diabetes mellitus and obesity on glucose transport and phosphorylation in skeletal muscle. (1996) (233)
Compensatory reallocation of brain resources supporting verbal episodic memory in Alzheimer's disease (1996) (232)
Amyloid PET imaging in Alzheimer’s disease: a comparison of three radiotracers (2014) (218)
Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. (2009) (217)
Effects of age and amyloid deposition on Aβ dynamics in the human central nervous system. (2012) (210)
Alzheimer disease and cognitive reserve: variation of education effect with carbon 11-labeled Pittsburgh Compound B uptake. (2008) (209)
Brain volume decline in aging: evidence for a relation between socioeconomic status, preclinical Alzheimer disease, and reserve. (2008) (206)
Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later (2013) (206)
Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer's pathology (2016) (201)
Four distinct trajectories of tau deposition identified in Alzheimer’s disease (2021) (200)
Antidepressant treatment normalizes hypoactivity in dorsolateral prefrontal cortex during emotional interference processing in major depression. (2009) (200)
Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline (2012) (198)
Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging (2013) (197)
Regional white matter hyperintensity burden in automated segmentation distinguishes late-life depressed subjects from comparison subjects matched for vascular risk factors. (2008) (193)
Demonstration in vivo of reduced serotonin responsivity in the brain of untreated depressed patients. (1996) (191)
An Antidepressant Decreases CSF Aβ Production in Healthy Individuals and in Transgenic AD Mice (2014) (187)
Dissolution kinetics of carboxylic acids I: effect of pH under unbuffered conditions. (1981) (182)
Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes. (2020) (174)
Regional cerebral blood flow and metabolism in reversible ischemia due to vasospasm. Determination by positron emission tomography. (1985) (173)
Use of Florbetapir-PET for Imaging-Amyloid Pathology (2011) (172)
Florbetapir F 18 amyloid PET and 36-month cognitive decline:a prospective multicenter study (2014) (171)
Regional Brain Activity Changes Associated with Fentanyl Analgesia Elucidated by Positron Emission Tomography (1997) (171)
Evaluation of 5-ethynyl-2′-deoxyuridine staining as a sensitive and reliable method for studying cell proliferation in the adult nervous system (2010) (170)
Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease (2013) (165)
Quantitative Analysis of PiB-PET with FreeSurfer ROIs (2013) (165)
Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology. (2011) (164)
Decreased hippocampal 5-HT2A receptor binding in major depressive disorder: in vivo measurement with [18F]altanserin positron emission tomography (2004) (162)
Ferritin levels in the cerebrospinal fluid predict Alzheimer's disease outcomes and are regulated by APOE (2015) (161)
The hippocampus and depression (2002) (156)
Human Brain Activity Response to Fentanyl Imaged by Positron Emission Tomography (1996) (148)
Dissolution kinetics of carboxylic acids II: effect of buffers. (1981) (146)
Amyloid‐beta plaque growth in cognitively normal adults: Longitudinal [11C]Pittsburgh compound B data (2011) (142)
Visinin‐like protein‐1: Diagnostic and prognostic biomarker in Alzheimer disease (2011) (140)
Increased lactate/pyruvate ratio augments blood flow in physiologically activated human brain. (2004) (139)
Strategies for in vivo Measurement of Receptor Binding Using Positron Emission Tomography (1986) (136)
Predicting Alzheimer’s disease progression using multi-modal deep learning approach (2019) (136)
Greater loss of 5-HT(2A) receptors in midlife than in late life. (2002) (128)
Diffuse Microstructural Abnormalities of Normal-Appearing White Matter in Late Life Depression: A Diffusion Tensor Imaging Study (2009) (126)
A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer’s disease dementia (2019) (124)
Amyloid deposition detected with florbetapir F 18 (18F-AV-45) is related to lower episodic memory performance in clinically normal older individuals (2013) (124)
A possible substrate for dopamine-related changes in mood and behavior: Prefrontal and limbic effects of a D3-preferring dopamine agonist (2002) (121)
Tau Positron‐Emission Tomography in Former National Football League Players (2019) (118)
Association of Cerebral Amyloid-&bgr; Aggregation With Cognitive Functioning in Persons Without Dementia (2018) (116)
Cerebral blood flow changes during vagus nerve stimulation for depression (2006) (115)
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease (2021) (113)
Potential Impact of Amyloid Imaging on Diagnosis and Intended Management in Patients With Progressive Cognitive Decline (2013) (111)
Regional Correction of Positron Emission Tomography Data for the Effects of Cerebral Atrophy (1988) (108)
Hexanucleotide repeat expansions in C9ORF72 in the spectrum of motor neuron diseases (2012) (104)
Tau PET in autosomal dominant Alzheimer’s disease: relationship with cognition, dementia and other biomarkers (2019) (103)
Quantifying pulmonary inflammation in cystic fibrosis with positron emission tomography. (2006) (100)
[11C]WAY 100635: a radioligand for imaging 5-HT1A receptors with positron emission tomography. (1994) (99)
Functional brain architecture is associated with the rate of tau accumulation in Alzheimer’s disease (2020) (96)
Positron Emission Tomographic Imaging of Serotonin Activation Effects on Prefrontal Cortex in Healthy Volunteers (1996) (95)
Relationship of dementia screening tests with biomarkers of Alzheimer's disease. (2010) (93)
Association between tau deposition and antecedent amyloid-&bgr; accumulation rates in normal and early symptomatic individuals (2017) (88)
FDG-PET imaging of pulmonary inflammation in healthy volunteers after airway instillation of endotoxin. (2006) (83)
Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale (2018) (82)
Integrated and automated data analysis method for neuronal activation studies using O-15 water PET (1993) (82)
Regulation of blood flow in activated human brain by cytosolic NADH/NAD+ ratio. (2006) (81)
Functional Neuroanatomy of Semantic Memory: Recognition of Semantic Associations (1999) (78)
Quantitative measurement of regional pulmonary blood flow with positron emission tomography. (1986) (78)
Kinetics of the Tau PET Tracer 18F-AV-1451 (T807) in Subjects with Normal Cognitive Function, Mild Cognitive Impairment, and Alzheimer Disease (2016) (77)
Decreased Hippocampal 5-HT2A Receptor Binding in Older Depressed Patients Using [18F]Altanserin Positron Emission Tomography (2004) (77)
Evaluation of a potential generator-produced PET tracer for cerebral perfusion imaging: single-pass cerebral extraction measurements and imaging with radiolabeled Cu-PTSM. (1990) (76)
Measurements of pulmonary vascular permeability with PET and gallium-68 transferrin. (1987) (76)
In Vivo Imaging of Human Limbic Responses to Nitrous Oxide Inhalation (1996) (75)
Non-coding variability at the APOE locus contributes to the Alzheimer’s risk (2019) (74)
Cerebral blood flow in hypertensive patients: an initial report of reduced and compensatory blood flow responses during performance of two cognitive tasks. (1998) (74)
Pulmonary vascular permeability during the adult respiratory distress syndrome: a positron emission tomographic study. (1988) (73)
Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study (2020) (71)
Positron tomographic assessment of 16 alpha-[18F] fluoro-17 beta-estradiol uptake in metastatic breast carcinoma. (1991) (70)
Robust Identification of Alzheimer’s Disease subtypes based on cortical atrophy patterns (2017) (69)
Dose-dependent Enhancement of In Vivo GABAA–Benzodiazepine Receptor Binding by Isoflurane (2001) (69)
Blast-related brain injury: imaging for clinical and research applications: report of the 2008 st. Louis workshop. (2009) (69)
Time-Related Increase of Oxygen Utilization in Continuously Activated Human Visual Cortex (2002) (68)
Florbetapir f-18: a histopathologically validated Beta-amyloid positron emission tomography imaging agent. (2011) (67)
In Vivo Imaging of Nitrous Oxide‐induced Changes in Cerebral Activation during Noxious Heat Stimuli (1997) (63)
An examination of regional cerebral blood flow during object naming tasks (1998) (62)
Comparison in animal models of 18F-spiroperidol and 18F-haloperidol: potential agents for imaging the dopamine receptor. (1983) (62)
Comparison of methods to quantitate 18F-FDG uptake with PET during experimental acute lung injury. (2004) (60)
Development of a PET radiotracer for non-invasive imaging of the reactive oxygen species, superoxide, in vivo. (2014) (60)
Brain blood-flow change with acute vagus nerve stimulation in treatment-refractory major depressive disorder (2012) (59)
A Semiautomated Method for Quantification of F 18 Florbetapir PET Images (2015) (59)
Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans (2012) (59)
Low-frequency repetitive transcranial magnetic stimulation to the temporoparietal junction for tinnitus. (2011) (58)
Association of Cerebral Metabolic Activity Changes with Vagus Nerve Stimulation Antidepressant Response in Treatment-Resistant Depression (2013) (58)
β-amyloid dynamics in human plasma. (2012) (58)
Flortaucipir F 18 Quantitation Using Parametric Estimation of Reference Signal Intensity (2017) (58)
Longitudinal measurement and hierarchical classification framework for the prediction of Alzheimer’s disease (2017) (58)
Improving CSF biomarker accuracy in predicting prevalent and incident Alzheimer disease (2011) (56)
Challenges and Opportunities with Causal Discovery Algorithms: Application to Alzheimer’s Pathophysiology (2020) (56)
Kinetic Modeling of the Tau PET Tracer 18F-AV-1451 in Human Healthy Volunteers and Alzheimer Disease Subjects (2017) (54)
Positron emission tomography and neuropathologic estimates of fibrillar amyloid-β in a patient with Down syndrome and Alzheimer disease. (2011) (53)
[18F]fluorodeoxyglucose positron emission tomography for lung antiinflammatory response evaluation. (2009) (52)
The BIN1 rs744373 SNP is associated with increased tau-PET levels and impaired memory (2019) (52)
PET brain mapping study of auditory verbal supraspan memory versus visual fixation in schizophrenia (1997) (50)
Functional neuroanatomy of verbal free recall: A replication study (1994) (50)
Noninvasive Estimation of the Arterial Input Function in Positron Emission Tomography Imaging of Cerebral Blood Flow (2013) (50)
Comparison of functional magnetic resonance imaging with positron emission tomography and magnetoencephalography to identify the motor cortex in a patient with an arteriovenous malformation. (1995) (49)
Role of family history for Alzheimer biomarker abnormalities in the adult children study. (2011) (49)
Development of a Positron Emission Tomography Radiotracer for Imaging Elevated Levels of Superoxide in Neuroinflammation (2017) (48)
Functional Connectivity in Auditory–Verbal Short-Term Memory in Alzheimer's Disease (1996) (48)
Cognitively unimpaired HIV-positive subjects do not have increased 11C-PiB (2010) (48)
Test–Retest Reproducibility for the Tau PET Imaging Agent Flortaucipir F 18 (2017) (46)
Cerebral perfusion response to successful treatment of depression with different serotoninergic agents. (2004) (45)
Alzheimer’s disease therapeutic trials: EU/US task force report on recruitment, retention, and methodology (2012) (45)
A method for the assessment of the functional neuroanatomy of human sleep using FDG PET. (1998) (45)
Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. (2022) (44)
Effect of CLU genetic variants on cerebrospinal fluid and neuroimaging markers in healthy, mild cognitive impairment and Alzheimer’s disease cohorts (2016) (44)
The kinetics of copper-62-PTSM in the normal human heart. (1992) (44)
PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer’s disease and Lewy body disorders (2014) (42)
Regional lung water and hematocrit determined by positron emission tomography. (1985) (42)
Multidentate (18)F-polypegylated styrylpyridines as imaging agents for Aβ plaques in cerebral amyloid angiopathy (CAA). (2011) (41)
Endogenous dopamine (DA) competes with the binding of a radiolabeled D3 receptor partial agonist in vivo: A positron emission tomography study (2011) (40)
Quantification of Tau Load Using [18F]AV1451 PET (2017) (40)
Cerebrospinal fluid biomarkers, education, brain volume, and future cognition. (2011) (39)
Human brain glucose metabolism may evolve during activation: Findings from a modified FDG PET paradigm (2006) (39)
Mining Outcome-relevant Brain Imaging Genetic Associations via Three-way Sparse Canonical Correlation Analysis in Alzheimer’s Disease (2017) (36)
Measurement of Regional Cerebral Blood Flow with Positron Emission Tomography: A Comparison of [15O]Water to [11C]Butanol with Distributed-Parameter and Compartmental Models (1993) (36)
PET amyloid imaging as a tool for early diagnosis and identifying patients at risk for progression to Alzheimer's disease (2011) (36)
[3H]4‐(dimethylamino)‐N‐(4‐(4‐(2‐methoxyphenyl)piperazin‐1‐yl) butyl)benzamide: A selective radioligand for dopamine D3 receptors. II. Quantitative analysis of dopamine D3 and D2 receptor density ratio in the caudate‐putamen (2010) (35)
Predicting Short-term MCI-to-AD Progression Using Imaging, CSF, Genetic Factors, Cognitive Resilience, and Demographics (2019) (35)
Quantitation of PET signal as an adjunct to visual interpretation of florbetapir imaging (2017) (35)
Neuropathologic heterogeneity does not impair florbetapir-positron emission tomography postmortem correlates. (2014) (34)
Regional changes in extravascular lung water detected by positron emission tomography. (1986) (34)
Alzheimer disease identification using amyloid imaging and reserve variables (2010) (34)
Imaging of Alzheimer's Disease (2003) (33)
Pretreatment cerebral metabolic activity correlates with antidepressant efficacy of vagus nerve stimulation in treatment-resistant major depression: a potential marker for response? (2012) (33)
Use of white matter reference regions for detection of change in florbetapir positron emission tomography from completed phase 3 solanezumab trials (2017) (33)
Effect of Amyloid Imaging on the Diagnosis and Management of Patients with Cognitive Decline: Impact of Appropriate Use Criteria (2016) (31)
Brain oxygen utilization measured with oxygen-15 radiotracers and positron emission tomography: generation of metabolic images. (1985) (30)
Cortical Binding of Pittsburgh Compound B, an Endophenotype for Genetic Studies of Alzheimer's Disease (2010) (30)
Genetic studies of plasma analytes identify novel potential biomarkers for several complex traits (2016) (28)
Dissolution kinetics of phenylbutazone. (1981) (27)
Women can bear a bigger burden: ante- and post-mortem evidence for reserve in the face of tau (2020) (26)
PET measurement of regional lung density: 1. (1986) (26)
Decreased tumor blood flow as measured by positron emission tomography in cancer patients treated with interleukin-1 and carboplatin on a phase I trial (2002) (26)
[3H]4‐(Dimethylamino)‐N‐[4‐(4‐(2‐methoxyphenyl)piperazin‐ 1‐yl)butyl]benzamide, a selective radioligand for dopamine D3 receptors. I. In vitro characterization (2009) (26)
Effectiveness of Florbetapir PET Imaging in Changing Patient Management (2017) (26)
Accelerated functional brain aging in pre-clinical familial Alzheimer’s disease (2021) (25)
Quantification of 18F-florbetapir PET: comparison of two analysis methods (2015) (25)
Dynamic measurements of local blood flow and metabolism in the study of higher cortical function in humans with positron emission tomography (1984) (25)
Alzheimer's disease identification using amyloid imaging and reserve variables: Proof of concept (2010) (24)
Evaluating pulmonary vascular permeability with radiolabeled proteins: an error analysis. (1990) (23)
18F-florbetapir Positron Emission Tomography–determined Cerebral &bgr;-Amyloid Deposition and Neurocognitive Performance after Cardiac Surgery (2018) (21)
Hydrocortisone induced regional cerebral activity changes in schizophrenia: a PET scan study (2002) (21)
Cascaded Multi-view Canonical Correlation (CaMCCo) for Early Diagnosis of Alzheimer’s Disease via Fusion of Clinical, Imaging and Omic Features (2017) (20)
Positive florbetapir PET amyloid imaging in a subject with frequent cortical neuritic plaques and frontotemporal lobar degeneration with TDP43-positive inclusions. (2014) (20)
A Novel Joint Brain Network Analysis Using Longitudinal Alzheimer’s Disease Data (2019) (19)
CHAPTER 16 – Scatter Correction for Brain Receptor Quantitation in 3D PET (1996) (19)
Comparison of regional flortaucipir PET with quantitative tau immunohistochemistry in three subjects with Alzheimer’s disease pathology: a clinicopathological study (2020) (19)
KL-VS heterozygosity is associated with lower amyloid-dependent tau accumulation and memory impairment in Alzheimer’s disease (2021) (19)
Aggregated Tau Measured by Visual Interpretation of Flortaucipir Positron Emission Tomography and the Associated Risk of Clinical Progression of Mild Cognitive Impairment and Alzheimer Disease (2021) (19)
Quantitation of pulmonary transgene expression with PET imaging. (2004) (19)
Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel‐based analysis for entorhinal cortex atrophy (2015) (18)
Antidepressant response to aripiprazole augmentation associated with enhanced FDOPA utilization in striatum: A preliminary PET study (2014) (17)
Antidepressant efficacy of olanzapine as monotherapy in major depressive disorder, without psychosis: A pilot study (2006) (17)
Levodopa effects on [ 11C]raclopride binding in the resting human brain (2015) (17)
Radiation dosimetry of florbetapir F 18 (2014) (16)
Genome-wide association analysis of hippocampal volume identifies enrichment of neurogenesis-related pathways (2016) (16)
Tau Subtypes of Alzheimer's Disease Determined in vivo Using Flortaucipir PET Imaging. (2019) (16)
Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer’s amyloid, tau and FDG PET status (2021) (16)
Regional Amyloid-β Load and White Matter Abnormalities Contribute to Hypometabolism in Alzheimer’s Dementia (2018) (15)
Alterations in Functional Neuroanatomical Connectivity in Alzheimer's Disease (1996) (14)
Severe hippocampal atrophy is not associated with depression in temporal lobe epilepsy (2014) (14)
Efficiency normalization techniques for 3D PET data (1995) (14)
Parametric methods for [18F]flortaucipir PET (2018) (14)
SAFETY, PHARMACOKINETICS (PK), AND FLORBETAPIR F-18 POSITRON EMISSION TOMOGRAPHY (PET) AFTER MULTIPLE DOSE ADMINISTRATION OF LY3002813, A β-AMYLOID PLAQUE-SPECIFIC ANTIBODY, IN ALZHEIMER’S DISEASE (AD) (2016) (13)
Incidence and clinical progression of placebo-treated amyloid-negative subjects with mild-to-moderate Alzheimer's disease (AD): Results from the phase III PET substudies of bapineuzumab and solanezumab (2013) (13)
Utilizing Advanced Imaging and Surrogate Markers Across the Spectrum of Alzheimer's Disease (2005) (12)
Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes (2022) (12)
Staging tau pathology with tau PET in Alzheimer’s disease: a longitudinal study (2021) (12)
The necessity for correcting for cerebral atrophy in global positron emission tomography measurements. (1984) (12)
Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI). (2019) (12)
National Cancer Institute workshop statement: Advances in clinical imaging using positron emission tomography, September 14-16, 1988 (1990) (12)
A semi-mechanism approach based on MRI and proteomics for prediction of conversion from mild cognitive impairment to Alzheimer’s disease (2016) (12)
Phase III trial results for the amyoid PET imaging agent Florbetapir F 18 (18F-AV-45): imaging to histopathologic correlations in an end-of-life human subject study (2010) (10)
Exploratory analyses of regional human brain distribution of the PET tau tracer F18-labeled T807 (AV-1541) in subjects with normal cognitive function or cognitive impairment thought to be due to Alzheimer's disease (2013) (10)
Relationships Between Cognition and Neuropathological Tau in Alzheimer's Disease Assessed by 18F Flortaucipir PET. (2021) (10)
The impact of PICALM genetic variations on reserve capacity of posterior cingulate in AD continuum (2016) (10)
The Centiloid Scale: Standardization of amyloid imaging measures (2013) (9)
Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer’s disease (2022) (9)
Tissue distribution kinetics of tetraethylammonium ion in the rat (1980) (9)
Higher CSF sTNFR1-related proteins associate with better prognosis in very early Alzheimer’s disease (2021) (9)
Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) (2012) (9)
Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease (2022) (9)
FAM222A encodes a protein which accumulates in plaques in Alzheimer’s disease (2020) (9)
Clinical PET: Aesop's tortoise? (1993) (9)
ltered Emotional Interference Processing in Affective nd Cognitive-Control Brain Circuitry in Major epression hristina (2008) (8)
A telescope GWAS analysis strategy, based on SNPs-genes-pathways ensamble and on multivariate algorithms, to characterize late onset Alzheimer’s disease (2020) (8)
[18F]spiroperidol: A radiopharmaceutical for the in vivo study of the dopamine receptor (1984) (8)
Pulmonary circulation, extravascular water, and solute flux as determined by positron emission tomography. (1987) (7)
A likely in vivo probe of human circadian timing system function using PET (1994) (7)
Relationships between 18F-AV-1451 (aka 18F-T807) PET Tau Binding and Amyloid Burden in Cognitively Normal Subjects and Patients with Cognitive Impairments Suspected of Alzheimer’s Disease (2015) (7)
Correlation between Alzheimer’s disease and type 2 diabetes using non-negative matrix factorization (2021) (7)
A predictive model using the mesoscopic architecture of the living brain to detect Alzheimer’s disease (2022) (7)
TRAILBLAZER-ALZ (NCT03367403): A PHASE 2 DISEASE-MODIFICATION COMBINATION THERAPY TRIAL TARGETING MULTIPLE MECHANISMS OF ACTION ALONG THE AMYLOID PATHWAY (2018) (7)
An automatic method for the quantification of uptake with Florbetapir imaging (2012) (7)
Results of a preliminary study of the potential of vasodilators for improving thermotherapy of deep-seated tumours [printed with original paging at end of 2(2); omitted from Int J Hyperthermia 1986 Jan-Mar;2(1)]. (1986) (7)
Patterns of relative cerebral blood flow in minor cognitive motor disorder in human immunodeficiency virus infection. (2015) (7)
MEASURING CHANGE IN BETA-AMYLOID BURDEN OVER TIME USING FLORBETAPIR-PET AND A SUBCORTICAL WHITE MATTER REFERENCE REGION (2014) (7)
Reproducibility Of Positron Emission Tomography (PET)-Measured [18F]Fluorodeoxyglucose ([18F]FDG) Uptake As A Marker Of Lung Inflammation In Chronic Obstructive Pulmonary Disease (COPD) (2011) (7)
CONVERSION OF AMYLOID QUANTITATION WITH FLORBETAPIR SUVR TO THE CENTILOID SCALE (2016) (7)
First case report: Image to autopsy correlation for tau imaging with [18F]-T808 (AV-680) (2013) (7)
Comprehensive analysis of epigenetic clocks reveals associations between disproportionate biological ageing and hippocampal volume (2022) (6)
Predicting Alzheimer’s disease progression using multi-modal deep learning approach (2019) (6)
SIGNIFICANT AND SUSTAINED FLORBETAPIR F18 UPTAKE REDUCTION IN PATIENTS WITH SYMPTOMATIC ALZHEIMER’S DISEASE WITH LY3002813, A β-AMYLOID PLAQUE-SPECIFIC ANTIBODY (2018) (6)
Dissociation of tau pathology and neuronal hypometabolism within the ATN framework of Alzheimer’s disease (2022) (6)
TRAILBLAZER‐ALZ Study: Dynamics of amyloid reduction after donanemab treatment (2021) (6)
Baseline Microglial Activation Correlates With Brain Amyloidosis and Longitudinal Cognitive Decline in Alzheimer Disease (2022) (6)
Correlation between two methods of florbetapir PET quantitative analysis. (2017) (6)
Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference (2018) (6)
Applications of positron emission tomography (1988) (6)
TEST-RETEST DATA FOR THE TAU PET IMAGING AGENT 18F-AV-1451 (PREVIOUSLY, 18F-T807) (2014) (5)
Design And Performance Of A Rotating Positron Tomograph, RPT-2 (1993) (5)
Results of multi-center clinical trials comparing four 18F PET amyloid-imaging agents: Preclinical to clinical correlations (2008) (5)
Positron emission tomography. (1990) (5)
Hypofrontality and working memory dysfunction in schizophrenia (1995) (5)
The BIN1 rs744373 SNP is associated with increased tau-PET levels and impaired memory (2019) (5)
An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE-ε4 in female patients with Alzheimer’s disease (2022) (5)
EU./U.S. CTAD Task Force on Alzheimer's Trial Populations. (2014) (5)
Central Mechanisms of Pain and Opioid Analgesia Elucidated by Positron Emission Tomography (1994) (5)
Re: Brain Blood-Flow Measurement with Bolus Intravenous H2 15O—Reply (1984) (5)
Laser stimulation for pain research (1996) (4)
G001: Cerebral blood flow in hypertensives: An initial report of reduced and compensatory blood flow responses during performance of two cognitive tasks (1998) (4)
Florbetapir-PET Imaging and Postmortem β-Amyloid Pathology—Reply (2011) (4)
Pet studies of voluntary saccadic eye movements and spatial working memory (1995) (4)
Effects of Hydrocortisone Infusion on rCBF in Schizophrenic Patients during a Memory Task. An O15 PET Study a (1994) (4)
Effect of CLU genetic variants on cerebrospinal fluid and neuroimaging markers in healthy, mild cognitive impairment and Alzheimer’s disease cohorts (2016) (4)
A randomized, controlled, multicenter, international study of the impact of florbetapir (18F) PET amyloid imaging on patient management and outcome (2015) (4)
EMPLOYING EARLY UPTAKE DATA FROM F18-FLORBETAPIR SCANS AS AN ESTIMATE OF REGIONAL CEREBRAL BLOOD FLOW: COMPARISON TO F18-FDG (2014) (4)
Use of florbetapir-PET to assess progression of amyloid burden over time (2012) (4)
Kinetic Modeling of Serotonin-1A Binding in Monkeys Using [11C]WAY 100635 and PET (1996) (4)
74 STRUCTURAL AND FUNCTIONAL IMAGING OF AFFECTIVE DISORDERS (2002) (4)
Positron emission tomography with 15oxygen radiopharmaceuticals. (1985) (4)
Cerebral responses to laser pain stimulus measured using positron emission tomography (1996) (4)
Overview of dominantly inherited AD and top‐line DIAN‐TU results of solanezumab and gantenerumab (2020) (4)
Dissection of the polygenic architecture of neuronal Aβ production using a large sample of individual iPSC lines derived from Alzheimer’s disease patients (2022) (4)
EARLY TAU DETECTION AND IMPLICATIONS FOR DISEASE PROGRESSION (2019) (3)
Cerebral metabolism with positron emission tomography and 0-15 radiopharmaceuticals. (1984) (3)
Longitudinal PIB PET imaging of the appearance and accumulation of beta-amyloid in cognitively normal middle and late life adults (2010) (3)
PET BIOMARKERS IN THE EXPEDITION 3 TRIAL OF PATIENTS WITH MILD AD (2017) (3)
Florbetapir (18F-AV-45) PET imaging of {beta}-amyloid plaques is highly correlated with histopathological assays at autopsy (2010) (3)
TAU PET IN A4: PRELIMINARY REPORT (2018) (3)
A prospective study on tumor hypoxia kinetics to implement hypoxic imaging-guided IMRT (2001) (3)
Challenges and Opportunities with Causal Discovery Algorithms: Application to Alzheimer’s Pathophysiology (2020) (3)
O.: II. Implementation and Validation 152 Brain Blood Flow Measured with Intravenous H (2006) (3)
Dynamic cerebral positron emission tomographic studies (1984) (3)
Glucose metabolism patterns: A potential index to characterize brain ageing and predict high conversion risk into cognitive impairment (2022) (3)
Functional brain architecture is associated with the rate of tau accumulation in Alzheimer’s disease (2020) (3)
Quantification of amyloid deposition with partial volume correction (2011) (2)
Cognitive decline and brain volume loss are signatures of cerebral A β deposition identified with PIB (2009) (2)
Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort (2022) (2)
Donanemab in Early Alzheimer's Disease. Reply. (2021) (2)
Correlation between baseline measures of amyloid-positron emission tomography (PET) imaging, cerebral spinal fluid (CSF) biomarkers, and clinical scales in predementia Alzheimer's disease (2011) (2)
A612 DOSE-DEPENDENT EFFECTS OF ISOFLURANE ON GABA sub A -RECEPTOR CONFORMATION IN VIVO IN HUMANS (1997) (2)
Quantifying the rate of beta-amyloid accumulation in cognitively normal participants using longitudinal [11C] PIB PET imaging (2010) (2)
Region-dependent kinetics of the Tau PET tracer [18 F]-AV-1451 (T807) (2015) (2)
Prognostic significance of florbetapir F18 PET imaging in MCI and mormal elderly: Final results from a longitudinal multicenter trial (2011) (2)
Levodopa-stimulated dopamine release in Tourette syndrome (2013) (2)
COMPARISON OF REGIONAL FLORTAUCIPIR PET TO QUANTITATIVE TAU AND AMYLOID IMMUNOASSAY IN PATIENTS WITH ALZHEIMER’S DISEASE PATHOLOGY: A PILOT CLINICO-PATHOLOGICAL STUDY (2017) (2)
The first 5 minutes of F18-Florbetapir scans as an estimate of regional cerebral blood flow and comparison to F18-FDG (2014) (2)
Quantitative comparison of three novel 18F-labeled ligands for PET imaging of brain amyloid-{beta} plaques in Alzheimer's disease (2008) (2)
Identifying the topology of 18F-AV-1451 (also known as T807) PET tau images for diagnosis and prognosis in neurodegenerative disorders (2015) (1)
Interference, facilitation and strategy development in stroop task performance: An 15OH20 pet study (1995) (1)
Rapid computer prediction of total body water in fluid overload. (1981) (1)
Development Of Scatter Correction Techniques For Quantitative 3D Rviaging In A Whole Body PET Scanner With The Septa Retracted (1993) (1)
Understanding the topology of 18F-AV-1451 (also known as T807) PET tau images in Alzheimer’s disease (2015) (1)
FDG and Amyloid Positron Emission Tomography (2008) (1)
Comparison of florbetapir-PET scans to postmortem beta-amyloid histopathology in 59 autopsy cases (2012) (1)
Region-dependent kinetics of the Tau PET tracer [18 F]-AV-1451 (T807) (2015) (1)
Effects of solanezumab versus placebo administration on biomarkers in people with mild-to-moderate Alzheimer's disease: Results from two phase III clinical trials (2013) (1)
Evaluation of a visual read method for flortaucipir PET Scans (2019) (1)
rCBF (015 PET) during cognitive and physiological stimulation in schizophrenics (1994) (1)
Prediction of total exchangeable body sodium from the early-tracer disappearance curve. (1980) (1)
Hippocampal sparing and limbic predominant tau subtypes of Alzheimer’s disease determined in vivo using [18F]-AV-1451 PET imaging (2015) (1)
Florbetapir PET correlates with cognitive decline, PIB PET and CSF markers in the ADNI database (2011) (1)
Isoflurane enhances in vivo gabaA receptor ligand binding in humans: Quantitative imaging by positron emission tomography (1996) (1)
Comparison of activation response using functional PET and MRI (1996) (1)
Linearized models for quantitative analysis of cerebral blood flow and oxygen extraction (2010) (1)
Connectome-mediated prediction of future tau-PET burden in Alzheimer’s disease (2020) (1)
Author Correction: Spread of pathological tau proteins through communicating neurons in human Alzheimer’s disease (2021) (1)
Clinicopathological Correlation: Dopamine and Amyloid PET Imaging with Neuropathology in Three Subjects Clinically Diagnosed with Alzheimer's Disease or Dementia with Lewy Bodies. (2021) (1)
TEMPORAL LOBE QUANTITATION OF FLORTAUCIPIR PET IMAGES MAY IMPROVE DETECTION OF INTERMEDIATE NEUROFIBRILLARY TANGLE PATHOLOGY IN AUTOPSY-VALIDATED CASES (2019) (1)
FreeSurfer in regional analysis of beta-amyloid deposition with [11C]PIB positron emission tomography (2011) (1)
Brain glucose uptake changes with total sleep deprivation (SD): — relationship to sleep and temperature (1994) (1)
IMPLEMENTATION OF DUAL-PHASE FLORBETAPIR PET IN THE MULTICENTER PHASE 2 NAVIGATE-AD CLINICAL TRIAL (2019) (1)
Relationships between cognitive assessments and spatial distribution of neuropathological tau as assessed by 18F AV-1451 PET scanning (2015) (1)
Anterior cingulate gyrus dysfunction and attentional pathology in schizophrenia (1996) (1)
Evaluation of regional distribution of the PET tau tracer 18F-AV1451 (also known as 18F-T807) using SUVr analysis and voxel wise parametric mapping (2015) (1)
The functional neuroanatomy of memory in schizophrenia: An O15H2O pet study during supraspan memory performance (1995) (1)
Oncologic imaging of tumor hypoxia by Cu-ATSM and correlating findings on Cu-ATSM PET scans to cellular markers that may predict for radiation response (2004) (1)
LOBAR CLASSIFICATION OF TAU PET IMAGES IN THE EXPEDITION-3 TRIAL (2018) (1)
Relationship of Florbetapir F18 PET Amyloid Plaque Neuroimaging with Future Cognitive Decline over 36 Months (2013) (1)
Can incorporation of a quantitative estimate of cortical to cerebellar SUVr as an adjunct to visual interpretation improve the accuracy and reliability of florbetapir PET scan interpretation (2014) (1)
AN UPDATE ON THE BINDING PROFILE OF FLORTAUCIPIR IN AD VERSUS NORMAL CNS PROTEINS AND NORMAL BRAIN (2017) (1)
Potential effect of amyloid imaging on diagnosis and intended management of patients with cognitive decline: Impact of appropriate use criterion (2013) (1)
Studying the pulmonary circulation with positron emission tomography (1988) (1)
Repetitive Transcranial Magnetic Stimulation for Tinnitus—Reply (2011) (1)
Ongoing development of analysis strategies with [F-18]-T807 (AV-1451): A PET biomarker for tau deposits (2014) (1)
Understanding the topology of 18F-AV-1451 (also known as T807) PET tau images in Alzheimer’s disease (2015) (1)
Solanezumab in‐depth outcomes (2020) (1)
Positron Emission Tomography: Clinical Status in the United States in 1987 (2006) (0)
APOE ε4 effects on florbetapir F18 PET in Alzheimer's disease, mild cognitive impairment and normal aging (2011) (0)
Correlation of the AD8: an Informant-Based Dementia Screening Tool with Amyloid Imaging and CSF Biomarkers of Alzheimer Disease (2010) (0)
P4-415 EFFECTIVENESS OF COMMUNITY-DWELLING GROUP VALIDATION THERAPY (CGVT) FOR DEMENTIA PATIENTS IN KOREA (2013) (0)
Noninvasive extraction of arterial input function for functional brain studies (2010) (0)
P3-440 COMPARINGTHECENTILOID SCALEFOR PITTSBURGH COMPOUND B AND FLORBETAPIR IN LONGITUDINAL PET STUDIES OF SPORADIC AD (2018) (0)
Methods and future directions for evaluation of Tau PET signal (2021) (0)
Prognostic value of 8F-Florbetapir scan: a 36-month follow up analysis using ADNI data (2015) (0)
O3-01-07 Relationship between in vivo amyloid imaging with 11C-PIB and CSF Aβ42 (2006) (0)
Predicting Short-term MCI-to-AD Progression Using Imaging, CSF, Genetic Factors, Cognitive Resilience, and Demographics (2019) (0)
Author Correction: FAM222A encodes a protein which accumulates in plaques in Alzheimer’s disease (2022) (0)
Lack of Substantial Progression of Cognitive Deficits in Patients with Negative Amyloid Imaging: Implications for Clinical Trials (P01.016) (2013) (0)
Early tau detection in flortaucipir images: validation in autopsy-confirmed data and implications for disease progression (2023) (0)
Predicting Symptomatic Alzheimer's Disease in Healthy Individuals With Amyloid Imaging (2010) (0)
Correlation of the AD8, an informant-based dementia screening tool, with amyloid imaging and CSF biomarkers of Alzheimer disease (2010) (0)
Dr. Carter and Colleagues Reply (1999) (0)
Semi-quantitative visual rating of Florpiramine F 18 (18F-AV -45) PET scans (2009) (0)
An Error Analysis of Pulmonary Vascular Permeability Measurements Made with Positron Emission Tomography (1990) (0)
Comparison of reference regions for improved detection of change in florbetapir PET from phase 3 solanezumab trials (2015) (0)
P2-016: Cortical binding of Pittsburgh compound B, an endophenotype for genetic studies of Alzheimer's disease (2008) (0)
[18F]T807 ([18F]AV-1451) and Fluorescent Analog T726 Bind to PHF-Tau but Not TDP-43 in Alzheimer’s and FTD Post-Mortem Brain Tissue Sections (2015) (0)
A blood-based signature of cerebrospinal fluid Aβ1–42 status (2019) (0)
Prognostic significance of Florbetapir (18F-Florbetapir) PET imaging for future cognitive performance in recently diagnosed MCI: Final results from a 3-year multicenter longitudinal trial (2012) (0)
P1–341: Withdrawn (2013) (0)
THE RELATIONSHIP OF [18F]AV-1451 PET TAU IMAGES TO CHANGES IN COGNITION OVER TIME (2016) (0)
APOE E4 effects on florbetapir F18 PET in Alzheimer's disease, mild cognitive impairment and normal aging (2011) (0)
Po-topic IV-01 (2003) (0)
JAMA Paper supplement (2015) (0)
Optimization of 15O-water activation studies in PET/CT (2009) (0)
CONVERSION OF AMYLOID QUANTITATION WITH FLORBETAPIR SUVR TO THE CENTILOID SCALE (2016) (0)
EVOLUTION OF [18F]AV-1451 PET TAU SIGNAL: INTERIM ANALYSIS OF AN 18-MONTH PHASE 2 STUDY (2016) (0)
The Novel Neuronal Injury Marker, Visinin-like Protein-1 (VILIP-1), as a Diagnostic and Prognostic Marker in Alzheimer's Disease (2010) (0)
LOBAR CLASSIFICATION OF TAU PET IMAGES IN THE EXPEDITION-3 TRIAL (2018) (0)
Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration (2020) (0)
Endogenous dopamine competes with the in vivo binding of an [18F]-labeled D3 partial agonist (2009) (0)
Reliability of visual interpretation of 5 min and 10 min florbetapir F18 scans from ADNI database (2013) (0)
SPAP and Avid florbetapir Analysis Methods (2013) (0)
IMAGE PATTERNS AND CLINICAL PHENOTYPES ASSOCIATED WITH FASTEST INCREASE OF TAU BURDEN MEASURED BY LONGITUDINAL [18F]-AV-1451 (T807) PET STUDIES (2016) (0)
The Polygenic Risk Score Knowledge Base offers a centralized online repository for calculating and contextualizing polygenic risk scores (2021) (0)
Comparison of reference regions for improved detection of change in florbetapir PET from phase 3 solanezumab trials (2015) (0)
Novel use of tau imaging to enrich for pathological homogeneity within the PERISCOPE‐ALZ study of zagotenemab (2021) (0)
Molecular markers associated with poor prognosis in hypoxic tumors of uterine cervix (2002) (0)
Network diffusion model enhances predictions of future tau‐PET burden in Alzheimer’s patients (2020) (0)
Comparison of amyloid burden in the brain using Florbetapir F 18 and 11C-PIB PET data (2011) (0)
Florbetapir PET Imaging Predicts Postmortem Amyloid Burden in Alzheimer's Disease Despite Presence of Other Neuropathologies (2013) (0)
Differential distribution of dopamine D2 and D3 receptors in the Rhesus brain measured with PET (2010) (0)
The management impact of [18F]AV-133 VMAT2 PET in atypical Parkinson’s disease (2014) (0)
USP STANDARDS FOR FLUMAZENIL C 11 INJECTION (1998) (0)
IC-P-054 Relationship between in vivo amyloid imaging with 11C-PIB and CSF Aβ42 (2006) (0)
EFFECT OF AMYLOID IMAGING ON DIAGNOSIS AND MANAGEMENT OF PATIENTS WITH COGNITIVE DECLINE: IMPACT OF APPROPRIATE USE CRITERIA (2014) (0)
COMPARING THE CENTILOID SCALE FOR PITTSBURGH COMPOUND B AND FLORBETAPIR IN LONGITUDINAL PET STUDIES OF SPORADIC AD (2018) (0)
IMAGE PATTERNS AND CLINICAL PHENOTYPES ASSOCIATED WITH FASTEST INCREASE OF TAU BURDEN MEASURED BY LONGITUDINAL [18F]-AV-1451 (T807) PET STUDIES (2016) (0)
Levodopa effects on ( C)raclopride binding in the resting human brain (version 1; referees: 3 approved) (2017) (0)
GenEpi: gene-based epistasis discovery using machine learning (2020) (0)
Compensatory Blood Flow Responses During Performance of Two Cognitive Tasks Cerebral Blood Flow in Hypertensive Patients : An Initial Report of Reduced and (2013) (0)
Reproducibility of an automatic method for quantification of Florbetapir F18 PET uptake (2012) (0)
COMPARING THE CENTILOID SCALE FOR PITTSBURGH COMPOUND B AND FLORBETAPIR IN LONGITUDINAL PET STUDIES OF SPORADIC AD (2018) (0)
Prevalence of beta-amyloid plaques in a nondemented population using [11C]PIB and PET: Impact of APOE genotype (2009) (0)
The trend of disruption in the functional brain network topology of Alzheimer’s disease (2021) (0)
Measurement of regional lung density by positron emission tomography (1985) (0)
Reduced regional fractional anisotropy in cognitively normal individuals with biochemical and imaging evidence of cerebral amyloid deposition (2010) (0)
IC-01-01: Cortical binding of Pittsburgh compound B, an endophenotype for genetic studies of Alzheimer's disease (2008) (0)
COMPARINGTHECENTILOIDSCALEFOR PITTSBURGH COMPOUND B AND FLORBETAPIR IN LONGITUDINAL PET STUDIES OF SPORADIC AD MEMORY ACROSS ALZHEIMER’S DISEASE SPECTRUM ARE ASSOCIATED WITH PATTERNS OF ATAU PROPAGATION PREDICTED BY BRAAK STAGING (2018) (0)
A novel diagnostic and prognostic fluid biomarker for early Alzheimer's disease: YKL-40 (2010) (0)
Toronto 07 : 30 – 08 : 00 Registration and Continental Breakfast 08 : 00 – 08 : 15 Introduction 08 : 15 – 09 : 30 Session 1 : Pathologic Correlations , Amyloid Positivity (2010) (0)
Quantitative amyloid imaging with FreeSurfer regions (2011) (0)
Room D, 10/17/2000 9: 00 AM - 11: 00 AM (PS) Isoflurane Potentiates GABAAReceptor-Mediated Metabolic Depression In Vivo: A Quantitative Positron Emission Tomography (PET) Study A-751 (2000) (0)
A binary classification method for visual evaluation of Florbetapir PET images (2012) (0)
The value of rACC in diagnosing dementia of Alzheimer type with 11C-PIB PET (2009) (0)
Spread of pathological tau proteins through communicating neurons in human Alzheimer’s disease (2020) (0)
Functional anatomy of selective attention in normals and schizophrenia (1995) (0)
Update on Tau imaging with F18-T807 (2014) (0)
DEBATE: MRI VERSUS PET: WHICH IMAGING MODALITY PROVIDES THE BEST BIOMARKER AND FOR WHICH PURPOSE? (2019) (0)
QUANTIFICATION OF TAU LOAD USING [18F]AV-1451 AND PET (2016) (0)
Interactive effects of a sedentary lifestyle and the APOE e4 allele on amyloid deposition (2011) (0)
O3-02-02: Update on the relationship between in vivo amyloid imaging with C-PIB and CSF Aβ42 (2008) (0)
Use of exploratory INDs in evaluation of 18F-labeled PET amyloid plaque imaging agents (2008) (0)
Determine optimal reference region to quantify Florbetapir F18 PET brain images (2011) (0)
Author Correction: Multimodal hippocampal subfield grading for Alzheimer’s disease classification (2020) (0)
MODELING OF TAU TRAJECTORIES ACROSS THE ALZHEIMER’S DISEASE SPECTRUM USING [18F]-FLORTAUCIPIR PET IMAGING (2017) (0)
Medication Use as a Confounding Factor in the Use of the Cerebrospinal Fluid tau/β-Amyloid42 Ratio—Reply (2007) (0)
Deep learning-based polygenic risk analysis for Alzheimer’s disease prediction (2023) (0)
460 Abnormal cortical physiology associated with selective attention dysfunction in schizophrenia (1997) (0)
Neuropathological diagnoses of subjects autopsied in the phase 3 clinicopathological study of flortaucipir F18 PET imaging (2020) (0)
REDUCED SEROTONIN RESPONSIVITY IN DEPRESSION. AUTHORS' REPLY (1997) (0)
FLORTAUCIPIR TAU BINDING AND REGIONALBRAINATROPHYINAMYLOID POSITIVE SUBJECTS ACROSS THE ALZHEIMER’S DISEASE SPECTRUM (2019) (0)
IC‐P‐172: Withdrawn (2015) (0)
Author Correction: Multimodal hippocampal subfield grading for Alzheimer’s disease classification (2020) (0)
PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 together distinguish Alzheimer's disease from DLB patients (2011) (0)
RELATIONSHIPS BETWEEN FLORTAUCIPIR TAU BINDING AND REGIONAL BRAIN ATROPHY IN AMYLOID POSITIVE SUBJECTS ACROSS THE ALZHEIMER’S DISEASE SPECTRUM (2019) (0)
Amyloid Imaging with Florbetapir-PET Correlates with Cognitive Performance in Non-Demented Oldest-Old (2011) (0)
Characteristic patterns of inter- and intra-hemispheric metabolic connectivity in patients with stable and progressive mild cognitive impairment and Alzheimer’s disease (2018) (0)
may yield important insights into genetic influences on the biology of Alzheimer’s disease (AD).We investigated the accuracy of a novel unsuper- vised multimodal biomarker classifier for differentiating cognitively normal elderly (NC) from subjects with amnestic mild cognitive impairment (2019) (0)
Pattern Discovery in Brain Imaging Genetics via SCCA Modeling with a Generic Non-convex Penalty (2017) (0)
Procedural pitfalls and artifacts utilizing Florbetapir F18, a novel PET brain radiotracer used for imaging {beta}-amyloid plaques, the hallmark pathology associated with Alzheimer's disease (2011) (0)
Reproducibility of applying multiple statistical analyses to data from the TRAILBLAZER‐ALZ clinical trial of donanemab in early symptomatic Alzheimer's disease (2021) (0)
Original Clinical Paper Comparison of Functional Magnetic Resonance Imaging with Positron Emission Tomography and Magnetoencephalography to Identifjr the Motor Cortex in a Patient with an Arteriovenous Malformation (1995) (0)
PARAMETRIC IMAGING OF TAU LOAD IN ALZHEIMER’S PATIENTS AND CONTROLS USING FLORTAUCIPIR (2017) (0)
Basic principles of amyloid PET imaging (2005) (0)
QUANTIFICATION OF TAU LOAD USING [18F]AV-1451 AND PET (2016) (0)
Regional Amyloid-β Load and White Matter Abnormalities Contribute to Hypometabolism in Alzheimer’s Dementia (2018) (0)
Parkinson's Progression Markers Initiative brain autopsy program. (2022) (0)
BRAINCHECK: A NEW SCREENING TOOL FOR COGNITIVE IMPAIRMENT IN THE ELDERLY e COMBINING PATIENT ASSESSMENT WITH CAREGIVER INFORMATION (2014) (0)
A management impact study of VMAT2 PET with [18F]AV-133 in patients with uncertain parkinsonian features: Preliminary findings (2013) (0)
IMAGING BIOMARKER TRAJECTORIES OF THE MILD AD DEMENTIA POPULATION IN THE EXPEDITION3 TRIAL (2019) (0)
Correlation of regional binding potential and MCBP for selected regions. (2013) (0)
Effects of Intravenous Solanezumab 400 mg q 4 Weeks vs. Placebo on Biomarkers in Patients with Mild to Moderate Alzheimer's Disease: Results of Two Phase 3 Studies (P01.011) (2013) (0)
SIGNAL AVERAGING APPLIED TO POSITRON EMISSION TOMOGRAPHY. (1987) (0)
ASSOCIATION BETWEEN APOE ISOFORM AND 18-MONTH TAU ACCUMULATION (2019) (0)
RELATIONSHIPS BETWEEN FLORTAUCIPIR TAU BINDING AND REGIONAL BRAIN ATROPHY IN AMYLOID POSITIVE SUBJECTS ACROSS THE ALZHEIMER’S DISEASE SPECTRUM (2019) (0)
Increased SNR of 3D+t Florbetapir-PET images using spatio-temporal diffusion (2012) (0)
PARAMETRIC IMAGING OF TAU LOAD IN ALZHEIMER’S PATIENTS AND CONTROLS USING FLORTAUCIPIR (2017) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Mark M. A. Mintun?

Mark M. A. Mintun is affiliated with the following schools:

Mark M. A. Mintun's Academic­Influence.com Rankings

Why Is Mark M. A. Mintun Influential?

Mark M. A. Mintun's Published Works

Published Works

What Schools Are Affiliated With Mark M. A. Mintun?

Mark M. A. Mintun's AcademicInfluence.com Rankings